Loading...
Loading...
India's rivaroxaban imports from MALTA total $244 across 3 shipments from 1 foreign suppliers. PHAROS MT LTD leads with $244 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include VEEDA CLINICAL RESEARCH PVT. LTD.. This corridor reflects India's pharmaceutical import demand for rivaroxaban — a concentrated sourcing relationship with select suppliers from MALTA.

PHAROS MT LTD is the leading Rivaroxaban supplier from MALTA to India, with import value of $244 across 3 shipments. The top 5 suppliers — PHAROS MT LTD — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | PHAROS MT LTD | $244 | 3 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | VEEDA CLINICAL RESEARCH PVT. LTD. | $244 | 3 | 100.0% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Rivaroxaban suppliers from MALTA to India include PHAROS MT LTD. The leading supplier is PHAROS MT LTD with import value of $244 USD across 3 shipments. India imported Rivaroxaban worth $244 USD from MALTA in total across 3 shipments.
India imported Rivaroxaban worth $244 USD from MALTA across 3 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Rivaroxaban sourced from MALTA include VEEDA CLINICAL RESEARCH PVT. LTD.. The largest buyer is VEEDA CLINICAL RESEARCH PVT. LTD. with $244 in imports across 3 shipments.
The total value of Rivaroxaban imports from MALTA to India is $244 USD, across 3 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists